Fig. 6.

Locomotor effects of 10 mg/kg spiradoline + 10 mg/kg buprenorphine (top) and 10 mg/kg nor-binaltorphimine + 10 mg/kg spiradoline + 10 mg/kg buprenorphine (bottom) over 5 days of treatment. Left, locomotor activity expressed as distance traveled (centimeters) after saline administration (SAL) and 5 days of drug treatment. Right, locomotor activity on days 1 and 5 expressed as difference from saline control values (centimeters). Significant differences are indicated as follows: a, significantly different from saline (p < 0.05); and b, significantly different from day1(p < 0.05).